Janssen’s psoriasis drug shows promise for childhood diabetes
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
Read More
Tag: Janssen
Intelligent OMICS partners with Janssen on AI-driven research
The AI platform and expertise will be combined to discover novel targets for haematological cancers
Read More
Janssen’s Talvey receives positive CHMP opinion
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma
Read More
Janssen reveals new Spravato data
Period to remission was shortened with esketamine nasal spray in both sub-groups within study
Read More
Janssen reveals data from erdafitinib study
Erdafitinib boosted survival in patients with certain conditions including metastatic urothelial carcinoma
Read More
NICE approval for Janssen’s Darzalex combination
Recommendation concerns routine use across the NHS as therapy for multiple myeloma
Read More
Janssen reaches Akeega approval milestone
Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer
Read More
Janssen’s Rybrevant yields positive data
Results from trial showed a long-term response among specific lung cancer population
Read More
Positive CHMP opinion for Janssen’s AKEEGA
If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU
Read More
Janssen reveals vital niraparib data
Research concerns the effect of niraparib when combined with abiraterone acetate plus prednisone
Read More
Janssen submits marketing application for talquetamab
European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma
Read More
Janssen’s teclistamab gets CMA from European Commission
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma
Read More
- Gobivaz approved across Europe as first Simponi biosimilar
- Poolbeg granted European patent for POLB 001
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
